Vigabatrin in the treatment of epilepsy: A double-blind, placebo-controlled study

A. Tartara, R. Manni, C. A. Galimberti, J. Hardenberg, J. Orwin, E. Perucca

Research output: Contribution to journalArticle

Abstract

The efficacy and tolerability of vigabatrin (γ-vinyl GABA, GVG) given as add-on therapy to 23 adult outpatients with severe drug-resistant epilepsy (17 with partial seizures), were studied using a double-blind, placebo-controlled, crossover design. The study consisted of two 7-week periods during which vigabatrin and placebo were administered in random sequence. Dosage was 1.0 g twice daily for patients weighing ≤65 kg and 1.5 g twice daily for patients weighing >65 kg. Three patients were dropped from the study, two for reasons unrelated to treatment and one because of the appearance of vertigo, headache, dysarthria, and ataxia, which subsided rapidly when vigabatrin was stopped (3 g daily). Sixteen of the 20 patients available for analysis showed a decrease in the total number of seizures as compared with the placebo period. Of these, 12 showed a >50% reduction in seizure frequency and 4 of the 12 showed a >75% reduction. Both the total number of seizures and the number of partial seizures were significantly reduced by vigabatrin (p <0.01). Only in the patient who dropped out were severe adverse effects seen. The most frequently reported unwanted effect was mild drowsiness, which developed in seven patients on vigabatrin and in one on placebo. Positive effects, however, were also seen with six patients who reported an improved sense of well-being while receiveing vigabatrin as compared with only 1 during the placebo period. No consistent changes in electrocardiogram (ECG), electroencephalogram (EEG), and visual-, auditory-, and somatosensory-evoked potentials were seen during the study. Serum levels of associated anticonvulsants remained unchanged, with the exception of a decrease in serum phenytoin during vigabatrin in the only phenytoin-treated patient. We conclude that add-on treatment with vigabatrin is effective and well tolerated in adult patients with drug-resistant epilepsy.

Original languageEnglish
Pages (from-to)717-723
Number of pages7
JournalEpilepsia
Volume27
Issue number6
Publication statusPublished - 1986

Fingerprint

Vigabatrin
Epilepsy
Placebos
Seizures
Therapeutics
Phenytoin
Dysarthria
Auditory Evoked Potentials
Somatosensory Evoked Potentials
Sleep Stages
Vertigo
Ataxia
Serum
Anticonvulsants
Cross-Over Studies
gamma-Aminobutyric Acid
Headache
Electroencephalography
Electrocardiography
Outpatients

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Vigabatrin in the treatment of epilepsy : A double-blind, placebo-controlled study. / Tartara, A.; Manni, R.; Galimberti, C. A.; Hardenberg, J.; Orwin, J.; Perucca, E.

In: Epilepsia, Vol. 27, No. 6, 1986, p. 717-723.

Research output: Contribution to journalArticle

@article{516a18706ba74147bf825ee2031c7a22,
title = "Vigabatrin in the treatment of epilepsy: A double-blind, placebo-controlled study",
abstract = "The efficacy and tolerability of vigabatrin (γ-vinyl GABA, GVG) given as add-on therapy to 23 adult outpatients with severe drug-resistant epilepsy (17 with partial seizures), were studied using a double-blind, placebo-controlled, crossover design. The study consisted of two 7-week periods during which vigabatrin and placebo were administered in random sequence. Dosage was 1.0 g twice daily for patients weighing ≤65 kg and 1.5 g twice daily for patients weighing >65 kg. Three patients were dropped from the study, two for reasons unrelated to treatment and one because of the appearance of vertigo, headache, dysarthria, and ataxia, which subsided rapidly when vigabatrin was stopped (3 g daily). Sixteen of the 20 patients available for analysis showed a decrease in the total number of seizures as compared with the placebo period. Of these, 12 showed a >50{\%} reduction in seizure frequency and 4 of the 12 showed a >75{\%} reduction. Both the total number of seizures and the number of partial seizures were significantly reduced by vigabatrin (p <0.01). Only in the patient who dropped out were severe adverse effects seen. The most frequently reported unwanted effect was mild drowsiness, which developed in seven patients on vigabatrin and in one on placebo. Positive effects, however, were also seen with six patients who reported an improved sense of well-being while receiveing vigabatrin as compared with only 1 during the placebo period. No consistent changes in electrocardiogram (ECG), electroencephalogram (EEG), and visual-, auditory-, and somatosensory-evoked potentials were seen during the study. Serum levels of associated anticonvulsants remained unchanged, with the exception of a decrease in serum phenytoin during vigabatrin in the only phenytoin-treated patient. We conclude that add-on treatment with vigabatrin is effective and well tolerated in adult patients with drug-resistant epilepsy.",
author = "A. Tartara and R. Manni and Galimberti, {C. A.} and J. Hardenberg and J. Orwin and E. Perucca",
year = "1986",
language = "English",
volume = "27",
pages = "717--723",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Blackwell Publishing Inc.",
number = "6",

}

TY - JOUR

T1 - Vigabatrin in the treatment of epilepsy

T2 - A double-blind, placebo-controlled study

AU - Tartara, A.

AU - Manni, R.

AU - Galimberti, C. A.

AU - Hardenberg, J.

AU - Orwin, J.

AU - Perucca, E.

PY - 1986

Y1 - 1986

N2 - The efficacy and tolerability of vigabatrin (γ-vinyl GABA, GVG) given as add-on therapy to 23 adult outpatients with severe drug-resistant epilepsy (17 with partial seizures), were studied using a double-blind, placebo-controlled, crossover design. The study consisted of two 7-week periods during which vigabatrin and placebo were administered in random sequence. Dosage was 1.0 g twice daily for patients weighing ≤65 kg and 1.5 g twice daily for patients weighing >65 kg. Three patients were dropped from the study, two for reasons unrelated to treatment and one because of the appearance of vertigo, headache, dysarthria, and ataxia, which subsided rapidly when vigabatrin was stopped (3 g daily). Sixteen of the 20 patients available for analysis showed a decrease in the total number of seizures as compared with the placebo period. Of these, 12 showed a >50% reduction in seizure frequency and 4 of the 12 showed a >75% reduction. Both the total number of seizures and the number of partial seizures were significantly reduced by vigabatrin (p <0.01). Only in the patient who dropped out were severe adverse effects seen. The most frequently reported unwanted effect was mild drowsiness, which developed in seven patients on vigabatrin and in one on placebo. Positive effects, however, were also seen with six patients who reported an improved sense of well-being while receiveing vigabatrin as compared with only 1 during the placebo period. No consistent changes in electrocardiogram (ECG), electroencephalogram (EEG), and visual-, auditory-, and somatosensory-evoked potentials were seen during the study. Serum levels of associated anticonvulsants remained unchanged, with the exception of a decrease in serum phenytoin during vigabatrin in the only phenytoin-treated patient. We conclude that add-on treatment with vigabatrin is effective and well tolerated in adult patients with drug-resistant epilepsy.

AB - The efficacy and tolerability of vigabatrin (γ-vinyl GABA, GVG) given as add-on therapy to 23 adult outpatients with severe drug-resistant epilepsy (17 with partial seizures), were studied using a double-blind, placebo-controlled, crossover design. The study consisted of two 7-week periods during which vigabatrin and placebo were administered in random sequence. Dosage was 1.0 g twice daily for patients weighing ≤65 kg and 1.5 g twice daily for patients weighing >65 kg. Three patients were dropped from the study, two for reasons unrelated to treatment and one because of the appearance of vertigo, headache, dysarthria, and ataxia, which subsided rapidly when vigabatrin was stopped (3 g daily). Sixteen of the 20 patients available for analysis showed a decrease in the total number of seizures as compared with the placebo period. Of these, 12 showed a >50% reduction in seizure frequency and 4 of the 12 showed a >75% reduction. Both the total number of seizures and the number of partial seizures were significantly reduced by vigabatrin (p <0.01). Only in the patient who dropped out were severe adverse effects seen. The most frequently reported unwanted effect was mild drowsiness, which developed in seven patients on vigabatrin and in one on placebo. Positive effects, however, were also seen with six patients who reported an improved sense of well-being while receiveing vigabatrin as compared with only 1 during the placebo period. No consistent changes in electrocardiogram (ECG), electroencephalogram (EEG), and visual-, auditory-, and somatosensory-evoked potentials were seen during the study. Serum levels of associated anticonvulsants remained unchanged, with the exception of a decrease in serum phenytoin during vigabatrin in the only phenytoin-treated patient. We conclude that add-on treatment with vigabatrin is effective and well tolerated in adult patients with drug-resistant epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=0022873445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022873445&partnerID=8YFLogxK

M3 - Article

C2 - 3536469

AN - SCOPUS:0022873445

VL - 27

SP - 717

EP - 723

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 6

ER -